<DOC>
	<DOCNO>NCT01868438</DOCNO>
	<brief_summary>The purpose study compare bioavailability two formulation ( tablet granules dispersion ) antimalarial drug Pyramax ( combination pyronaridine artesunate ) .</brief_summary>
	<brief_title>Relative Bioavailability Pyronaridine-artesunate Tablet Granule Formulations , Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Pyronaridine</mesh_term>
	<criteria>Healthy male and/or female subject age 20 45 year , inclusive . ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) Weight 50 kg 80 kg Body Mass Index ( BMI ) calculate use Quetelet 's Index weight ( kg ) /height ( m2 ) 18.5 27 kg/m2 ; An informed consent document sign date subject ( prior screening study activity , include discontinuation prohibit medication ) Strictly normal value alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , bilirubin , normal abnormal clinically insignificant result blood urine laboratory parameter screen . Female subject nonchildbearing potential [ i.e. , physiologically incapable become pregnant , include female postmenopausal ( i.e. , one year without menses ) undergone sterilization ( via hysterectomy bilateral tubal ligation ) ] Female subject childbearing potential negative urine pregnancy test screening , negative pregnancy blood test admission , : agree double barrier method contraception 4 week first study drug administration throughout entire study follow period , whose partner undergone vasectomy negative sperm least 6 month Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Known history evidence clinically significant disorder cardiovascular ( include arrhythmia , acute correct QT interval ( QTc ) great equal 450 millisecond ) , respiratory ( include active tuberculosis ) , hepatic , renal , gastrointestinal , immunological ( include active HIVAIDS ) , neurological ( include auditory ) , endocrine , infectious , malignancy , psychiatric abnormality ( include head trauma ) Known history hypersensitivity , allergic adverse reaction pyronaridine artesunate artemisinins Known active Hepatitis A IgM ( HAVIgM ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( HCV Ab ) Seropositive HIV antibody , seropositive syphilis [ Syphilis reagin test ( + ) ] Previous exposure pyronaridineartesunate ( Pyramax ) Present recent history ( last two year ) tobacco abuse ( â‰¥10 cigarettes/day ) Known suspect alcohol abuse illicit drug use 5 year study start positive finding urine drug screen Intake alcoholic beverage caffeinecontaining food beverage , coffee , tea , chocolate , cola , 48 hour study drug administration Intake grapefruit , Seville oranges product contain 72 hour start study drug administration Gilbert 's disease Use overthecounter ( OTC ) medication , include vitamin , analgesic , antipyretic antacid within 7 day study drug administration Use prescription medication within 14 day start study drug administration require chronic use prescription medication Use enzymealtering agent ( e.g . barbiturate , phenothiazine , cimetidine , etc . ) within 30 day start study drug administration Plasma donation within 60 day start study drug administration Blood donation 500 mL within 60 day start study drug administration Participation AND drug administration clinical study within 60 day start study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Pyronaridine artesunate tablet</keyword>
	<keyword>Pyronaridine artesunate granule</keyword>
	<keyword>Pyramax tablet</keyword>
	<keyword>Pyramax granule</keyword>
	<keyword>Bioavailability</keyword>
</DOC>